Skip Navigation

Your Environment. Your Health.

Person Details

Superfund Research Program

Clement E. Furlong

University of Washington
Department of Medicine and Genome Sciences
Division of Medical Genetics
Seattle, WA 98195
Phone: (206) 543-1193
Fax: (206) 543-3050
Email: clem@u.washington.edu

Projects

Research Briefs

Patents

Publications

2016

  • Marsillach J, Costa LG, Furlong CE. 2016. Paraoxonase-1 and early life environmental exposures. Ann Glob Health(in press)

2015

2014

2013

  • Baker PE, Cole TB, Cartwright M, Suzuki SM, Thummel KE, Lin YS, Co AL, Rettie AE, Kim JH, Furlong CE. 2013. Identifying safer anti-wear triaryl phosphate additives for jet engine lubricants. Chem Biol Interact203(1):257-264. doi:10.1016/j.cbi.2012.10.005
  • Costa LG, Giordano G, Cole TB, Marsillach J, Furlong CE. 2013. Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity. Toxicology307:115-122. doi:10.1016/j.tox.2012.07.011
  • Costa LG, Tait L, de Laat R, Dao K, Giordano G, Pellacani C, Cole TB, Furlong CE. 2013. Modulation of paraoxonase 2 (PON2) in mouse brain by the polyphenol quercetin: A mechanism of neuroprotection?. Neurochem Res 38(9):1809-1818. doi:10.1007/s11064-013-1085-1
  • Giordano G, Tait L, Furlong CE, Cole TB, Kavanagh TJ, Costa LG. 2013. Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression. Free Radical Biology and Medicine58:98-108. doi:10.1016/j.freeradbiomed.2013.01.019
  • Kim D, Marsillach J, Furlong CE, Jarvik GP. 2013. Pharmacogenetics of paraoxonase activity: Elucidating the role of high-density lipoprotein in disease. Pharmacogenomics 14:1495-1515. doi:10.2217/pgs.13.147
  • Marsillach J, Costa LG, Furlong CE. 2013. Protein adducts as biomarkers of exposure to organophosphorus compounds. Toxicology307:46-54. doi:10.1016/j.tox.2012.12.007
  • Marsillach J, Hsieh EJ, Richter RJ, MacCoss MJ, Furlong CE. 2013. Proteomic analysis of adducted butyrylcholinesterase for biomonitoring organophosphorus exposures. Chem Biol Interact203(1):85-90. doi:10.1016/j.cbi.2012.10.019

2012

2011

  • Cole TB, Beyer RP, Bammler TK, Park SS, Farin FM, Costa LG, Furlong CE. 2011. Repeated Developmental Exposure of Mice to Chlorpyrifos Oxon Is Associated with Paraoxonase 1 (PON1)-Modulated Effects on Cerebellar Gene Expression. Toxicological Sciences123:155-169. doi:10.1093/toxsci/kfr157
  • Costa LG, Furlong CE. 2011. Paraoxonase 1: Structure, Function and Polymorphisms. Chapter 7 in: Anticholinesterase Pesticides: Metabolism, Neurotoxicity, and Epidemiology. Wiley, Hoboken, NJ. pp.85-96.
  • Costa LG, Giordano G, Furlong CE. 2011. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: The hunt goes on. Biochem Pharmacol81(3):337-344. doi:10.1016/j.bcp.2010.11.008
  • Giordano G, Cole TB, Furlong CE, Costa LG. 2011. Paraoxonase 2 (PON2) in the mouse central nervous system: A neuroprotective role?. Toxicol Appl Pharmacol256:369-378. doi:10.1016/j.taap.2011.02.014
  • Kim JH, Stevens RC, MacCoss MJ, Goodlett DR, Scherl A, Richter RJ, Suzuki SM, Furlong CE, Marsillach J, Tomazela D, Schopfer LM, Lockridge O. 2011. Biomarkers of organophosphorus (OP) exposures in humans. Neurotoxicology32:656-660. doi:10.1016/j.neuro.2011.06.005
  • Liyasova M, Li B, Schopfer LM, Nachon F, Masson P, Furlong CE, Lockridge O. 2011. Exposure to tri-o-cresyl phosphate detected in jet airplant passengers. Toxicol Appl Pharmacol256:337-347. doi:10.1016/j.taap.2011.06.016

2010

  • Cole TB, Park SS, Li WF, Furlong CE, Costa LG, Jansen KL. 2010. The Toxicity of Mixtures of Specific Organophosphorus (OP) Compounds is Modulated by Paraoxonase 1 Status. Adv Exp Med Biol660:47-60. doi:10.1007/978-1-60761-350-3_6
  • Furlong CE, Suzuki SM, Stevens RC, Marsillach J, Richter RJ, Jarvik GP, Checkoway H, Samii A, Costa LG, Griffith A, Roberts JW, Yearout D, Zabetian CP. 2010. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact187(1-3):355-361. doi:10.1016/j.cbi.2010.03.033
  • Hofmann JN, Keifer M, Checkoway H, De Roos AJ, Farin FM, Fenske RA, Richter RJ, van Belle G, Furlong CE. 2010. Biomarkers of Sensitivity and Exposure in Washington State Pesticide Handlers. Adv Exp Med Biol660:19-27. doi:10.1007/978-1-60761-350-3_3
  • Hofmann JN, Keifer M, De Roos AJ, Fenske RA, Furlong CE, van Belle G, Checkoway H. 2010. Occupational determinants of serum cholinesterase inhibition among organophosphate-exposed agricultural pesticide handlers in Washington State. Occup Environ Med67:375-386. doi:10.1136/oem.2009.046391
  • Kim JH, Stevens RC, MacCoss MJ, Goodlett DR, Scherl A, Richter RJ, Suzuki SM, Furlong CE. 2010. Identification and Characterization of Biomarkers of Organophosphorus (OP) Exposures in Humans. Adv Exp Med Biol660:61-71. doi:10.1007/978-1-60761-350-3_7
  • Richter RJ, Cole TB, Park SS, Otto TC, Cerasoli DM, Lenz DE, Furlong CE, Suzuki SM, Stevens RC. 2010. Engineering Human P0N1 in an E. coli Expression System. In: Paraoxonases in Inflammation, Infection and Toxicology. Humana Press, pp.37-46.
  • Richter RJ, Jarvik GP, Furlong CE. 2010. Paraoxonase 1 Status as a Risk Factor for Disease or Exposure. Adv Exp Med Biol660:29-35. doi:10.1007/978-1-60761-350-3_4
  • Ross S, Brewin C, Curran H, Furlong CE, Abraham-Smith K, Harrison V. 2010. Neuropsychological and psychiatric functioning in sheep farmers exposed to low levels of organophosphate pesticides. Neurotoxicol Teratol32(4):452-459. doi:10.1016/j.ntt.2010.03.004
  • Schopfer L, Furlong CE, Lockridge O. 2010. Development of diagnostics in the search for an explanation of aerotoxic syndrome. Anal Biochem404(1):64-74. doi:10.1016/j.ab.2010.04.032
  • Suzuki SM, Stevens RC, Richter RJ, Cole TB, Park SS, Otto TC, Cerasoli DM, Lenz DE, Furlong CE. 2010. Engineering Human PON1 in an E. coli Expression System. Adv Exp Med Biol660:37-45. doi:10.1007/978-1-60761-350-3_5
  • Ticozzi N, LeClerc AL, Keagle PJ, Glass JD, Wills AM, van Blitterswijk M, Bosco DA, Rodriguez-Leyva I, Gellera C, Ratti A, Taroni F, McKenna-Yasek D, Sapp PC, Silvani V, Furlong CE, Brown RH, Landers JE. 2010. Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann Neurol68(1):102-107. doi:10.1002/ana.21993

2009

2008

2007

  • Furlong CE. 2007. Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds. J Biochem Mol Toxicol21(4):197-205.

2006

  • Costa LG, Cole TB, Furlong CE. 2006. Gene-environment interactions: Paraoxonase (PON1) and sensitivity to organophosphate toxicity. LabMedicine37(2):109-113.
  • Costa LG, Cole TB, Furlong CE. 2006. Genetic ponymorphisms of human paraoxonase (PON1) and susceptibility to organophosphorous insecticide toxicity. In: 28th International Congress on Occupational Health (ICOH); May 11-16. Milan, Italy.
  • Costa LG, Cole TB, Furlong CE. 2006. PON1 and organophosphate toxicity. In: 2nd International Conference on paraoxonases; September 7-10. Debrecen, Hungary.
  • Costa LG, Cole TB, Vitalone A, Furlong CE. 2006. Paraoxonase polymorphisms and toxicity of organophosphates. Toxicology of Organophosphate and Carbamate Pesticides
  • Furlong CE. 2006. A surface plasmon resonance (SPR)-based sensor system for near real-time monitoring of analytes. In: Center for Process Analytical Chemistry Fall Sponser Meeting, November 7-10. Seattle, WA.
  • Furlong CE, Cole TB, Richter RJ, Brophy V, Carlson CS, Rieder R, Nickerson DA, Costa LG, Ranchalis J, Jarvik GP, Lusis AJ, Shih DM, Tward A. 2006. The functional consequences of polymorphisms in the human PON1 gene. In: 2nd International Conference on paraoxonases; September 7-10. Debrecen, Hungary.

2005

  • Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. 2005. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics15(8):589-598.
  • Costa LG, Cole TB, Furlong CE. 2005. Paraoxonase (PON1): from toxicology to cardiovascular medicine. Acta Bio-Medica de I Ateneo Parmense 76Suppl.2:50-57.
  • Costa LG, Cole TB, Vitalone A, Furlong CE. 2005. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clinica Chimica Acta352(1-2):37-47.
  • Costa LG, Vitalone A, Cole TB, Furlong CE. 2005. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol69(4):541-550.
  • Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward A, Lusis AJ, Costa LG. 2005. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology26(4):651-659.
  • Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG. 2005. Paraoxonase 1 (PON1) status and risk of insecticide exposure. J Biochem Mol Toxicol19(3):182-183.

2004

  • Costa LG, Kelada SN, Costa-Mallen P, Farin FM, Viernes HA, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H, Furlong CE. 2004. Paraoxonase 2 (PON2) polymorphisms and Parkinson's disease. Neuroscience Research Communications34(3):130-135.
  • Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward A, Lusis AJ, Costa LG. 2004. Role of paraoxonase (PON1) status in pesticide sensitivity; genetic and temporal determinants. Neurotoxicology26(4):651-659.

2003

  • Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE. 2003. Expression of human paraoxonase (PON1) during development. Pharmacogenet Genomics13(6):357-364.
  • Costa LG, Cole TB, Furlong CE. 2003. Polymorphisms of paraoxonse (PONl)and their significance in clinical toxicology of organophosphates. Toxicology41(1):37-45.
  • Costa LG, Cole TB, Jarvik GP, Furlong CE. 2003. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med54:371-392.
  • Costa LG, Richter RJ, Li WE, Cole TB, Guizzetti M, Furlong CE. 2003. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers8(1):1-12.
  • Kelada SN, Costa-Mallen P, Checkoway H, Viernes HA, Farin FM, Costa LG, Longstreth WT, Furlong CE, Jarvik GP, Swanson PD. 2003. Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry74(4):546-547.

2002

  • Costa LG, Furlong CE. 2002. Perspectives in PONI research. Chapter 10. In: Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Kluwer Academic Publishers, pp.197-210.
  • Costa LG, Li WF, Richter RJ, Shih DM, Lusis AJ, Furlong CE. 2002. PONl and organophosphate toxicity. Chapter 8. In: Paraoxonase (PON1) in Health and Disease: Basic and Clinical Aspects. Kluwer Academic Publishers, pp.165-183.
  • Furlong CE, Cole TB, Jarvik GP, Costa LG. 2002. Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenet Genomics3(3):341-348.

Back to Top

Share This Page:

Page Options:

Request Translation Services